Interactive Financial Advisors Exits Position in BAXALTA INC COM (BXLT)

BAXALTA INC COM (BXLT) : Interactive Financial Advisors has sold out all of its stake in BAXALTA INC COM during the most recent quarter, according to the disclosure filed by the company on Apr 21, 2016 with the SEC. The investment management company has sold out 16 shares of BAXALTA INC COM which is valued at $662.

BAXALTA INC COM closed down -0.42 points or -1.02% at $40.8 with 41,40,444 shares getting traded on Wednesday. Post opening the session at $41.03, the shares hit an intraday low of $40.69 and an intraday high of $41.25 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

Other Hedge Funds, Including , Seaward Management Limited Partnership reduced its stake in BXLT by selling 3,923 shares or 6.22% in the most recent quarter. The Hedge Fund company now holds 59,142 shares of BXLT which is valued at $2,447,296. BAXALTA INC COM makes up approx 0.13% of Seaward Management Limited Partnership’s portfolio.Reilly Financial Advisors reduced its stake in BXLT by selling 9,002 shares or 3.52% in the most recent quarter. The Hedge Fund company now holds 246,928 shares of BXLT which is valued at $10,217,881. BAXALTA INC COM makes up approx 2.23% of Reilly Financial Advisors’s portfolio.Community Bank N.a. reduced its stake in BXLT by selling 500 shares or 76.34% in the most recent quarter. The Hedge Fund company now holds 155 shares of BXLT which is valued at $6,414.Addison Capital Co reduced its stake in BXLT by selling 785 shares or 2.92% in the most recent quarter. The Hedge Fund company now holds 26,106 shares of BXLT which is valued at $1,057,554. BAXALTA INC COM makes up approx 0.80% of Addison Capital Co’s portfolio.

On the company’s financial health, BAXALTA INC COM reported $0.57 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Feb 16, 2016. Analyst had a consensus of $0.55. The company had revenue of $1763.00 million for the quarter, compared to analysts expectations of $1712.08 million. The company’s revenue was up 4.8% compared to the same quarter last year.

Baxalta Incorporated is a biopharmaceutical company. The Company develops manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute medical conditions. The Company also focuses on disease areas including oncology as well as technology platforms including gene therapy and biosimilars. The Company has a portfolio of various therapies that address unmet medical needs across various disease areas including hemophilia immunology and oncology. The Company’s products include ADVATE RECOMBINATE HEMOFIL M Immunate Immunine PROTHROMPLEX TOTAL RIXUBIS FACTOR VII NF BEBULIN FEIBA OBIZUR GAMMAGARD LIQUID GAMMAGARD S/D Subcuvia HYQVIA FLEXBUMIN BUMINATE ARALAST NP GLASSIA NP CEPROTIN and ANTITHROMBIN III IMMUNO.

Leave a Reply

BAXALTA INC COM - Is it time to Sell?

Top Brokerage Firms are advising their investors on BAXALTA INC COM. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.